AIM
HAE icon

Acrospire Investment Management’s Haemonetics HAE Stock Holding History

Acrospire Investment Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,300
Closed -$51K – 616
2017
Q2 		$51K Sell
1,300
-200
-13% -$8.21K 0.05% 831
2017
Q1 		$61K Sell
1,500
-3,300
-69% -$129K 0.05% 755
2016
Q4 		$193K Buy
4,800
+1,400
+41% +$52.8K 0.08% 384
2016
Q3 		$123K Buy
+3,400
New +$117K 0.08% 385
2016
Q2 		– Sell
-1,200
Closed -$42K – 2116
2016
Q1 		$42K Buy
+1,200
New +$38.8K 0.03% 1099

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Acrospire Investment Management's HAE Position: Q3 2017 in Review

Acrospire Investment Management sold out of Haemonetics (HAE) in Q3 2017, closing a stake of 1,300 shares — an estimated $51K sold.

Acrospire Investment Management first reported a position in HAE in Q1 2016 and held it in 5 quarters. The position peaked at $193K in Q4 2016. 207 funds tracked by Wall St. Rank hold HAE as of Q3 2017.

  • Acrospire Investment Management reported no remaining Haemonetics position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 1,300 Haemonetics shares in Q3 2017, an estimated $51K.
  • Acrospire Investment Management first reported a position in Haemonetics in Q1 2016 and held it in 5 quarters.
  • Acrospire Investment Management's Haemonetics position peaked at $193K in Q4 2016.
  • 207 funds tracked by Wall St. Rank held Haemonetics as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.